Fulgent Genetics, Inc. revised earnings guidance for the full year 2021. For the year 2021, the company now expects total revenue of approximately $930 million versus previous guidance of $800 million. Core Revenue of approximately $115 million versus previous guidance of $110 million, representing growth of 215% year-over-year. GAAP income of approximately $15.50 per share.